Results 171 to 180 of about 457,473 (371)

Association between Polymorphism in the Janus Kinase 2 (JAK2) Gene and Selected Performance Traits in Cattle and Sheep. [PDF]

open access: yesAnimals (Basel), 2023
Oster N   +5 more
europepmc   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender   +2 more
wiley   +1 more source

Age- and gender-based frequency and association of common myeloproliferative mutations in a South African cohort

open access: yesAfrican Journal of Laboratory Medicine
Background: Age, gender, and mutation type are key risk factors for myeloproliferative neoplasms (MPNs). Africa remains under-represented in global cancer statistics due to limited population-based genomic data.
Bathabile Mbele   +2 more
doaj   +1 more source

Experimental Pharmacological Management of Psoriasis

open access: yesJournal of Experimental Pharmacology, 2021
Elena Campione,1 Terenzio Cosio,1 Monia Di Prete,2 Caterina Lanna,1 Annunziata Dattola,1 Luca Bianchi1 1Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, 00133, Italy; 2Anatomic Pathology, University of Rome Tor ...
Campione E   +5 more
doaj  

Supplementary Figure 2 from Pyridone 6, A Pan-Janus–Activated Kinase Inhibitor, Induces Growth Inhibition of Multiple Myeloma Cells [PDF]

open access: gold, 2023
Laura Pedranzini   +7 more
openalex   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won   +11 more
wiley   +1 more source

Role of Plasma Janus Kinase 2 in Assessment of Disease Activity in Ulcerative Colitis

open access: yesSVU - International Journal of Medical Sciences
Background: Ulcerative colitis (UC) is a chronic autoimmune disease with increasing incidence worldwide. The pathophysiology of UC is multifactorial, including interplay between immune, gut microbiota, genetic vulnerability, and environment-related ...
Asmaa Mahdy Ghaith   +4 more
doaj   +1 more source

Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor [PDF]

open access: bronze, 2007
Akihiro Muto   +12 more
openalex   +1 more source

Home - About - Disclaimer - Privacy